<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52032">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01994330</url>
  </required_header>
  <id_info>
    <org_study_id>RVA</org_study_id>
    <nct_id>NCT01994330</nct_id>
  </id_info>
  <brief_title>Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery</brief_title>
  <official_title>Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <authority>Chile: Comité de Ética Científico</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acquired Von Willebrand disease (type 2A) has been described in patients with severe aortic
      stenosis, the association of aortic stenosis and Digestive bleeding due to this phenomena
      has received the name of Heye´s syndrome.

      We propose that administering Desmopressin (DDAVP) in patients scheduled to aortic valve
      replacement surgery will reduce blood loss and transfusion rate.

      this was a pilot study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized Controlled trial compared with placebo in a double blind fashion. Subjects with
      severe aortic stenosis (transvalvular gradient &gt;50 mmHg or valvular area of lass than 1 cm2)
      scheduled for aortic valve replacement were enrolled.

      the day of surgery blood samples were taken in order to confirm diagnosis (factor VIII
      activity and Protein electrophoresis for Von Willebrand´s multimers) and then 0,3 mcg/k of
      DDAVP or saline equally labeled as &quot;study drug&quot; were administered en 30 minutes a half hour
      before incision.

      Blood loss, postoperative hematocrit and transfusion requirement were measured, plasma
      sodium was measured as a safety issue.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>blood loss</measure>
    <time_frame>once patient arrives to post anesthesia care unit (approximately 6 hours after drug administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood loss obtained from fluid balance of surgery plus drain output</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative hematocrit</measure>
    <time_frame>the morning after surgery (18-24 hours after drug administration)</time_frame>
    <safety_issue>No</safety_issue>
    <description>hematocrit and hemoglobin in time frame mentioned</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need of transfusion</measure>
    <time_frame>48 hours post administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>transfusion of packaged red cells units until 48 hours after administration of study drug</description>
  </secondary_outcome>
  <other_outcome>
    <measure>incidence of hyponatremia</measure>
    <time_frame>18-24 hours post administration of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>blood sampling for plasma sodium in specified time frame</description>
  </other_outcome>
  <other_outcome>
    <measure>von Willebrand study and protein electrophoresis</measure>
    <time_frame>the day of surgery, half hour previos to administration of study drug</time_frame>
    <safety_issue>No</safety_issue>
    <description>blood sampling for von Willebrand study:
collagen binding activity
ristocetin factor test
coagulation factor VIII activity
von Willebrand factor antigen
Ristocetin cofactor test/von Willebrand factor antigen ratio and protein electrophoresis of von Willebrand multimers</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Acquired Von Willebrand Disease Secondary to Severe Aortic Stenosis</condition>
  <condition>Heye´s Syndrome</condition>
  <condition>Severe Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Desmopressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0,3 mcg per kilogram of desmopressin in 100 ml of saline, labeled as &quot;study drug&quot; and administered  in 30 minutes a half hour before surgical incision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 of saline labeled as &quot;study drug&quot; administered in 30 minutes a half hour before surgical incision</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desmopressin</intervention_name>
    <description>0.3 mcg per kilogram administered in 30 minutes a half hour previous to surgical incision</description>
    <arm_group_label>Desmopressin</arm_group_label>
    <other_name>DDAVP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe aortic stenosis defined as mean transvalvular gradient greater or equal to 40
             mmHg ot transvalvular area less than 1 cm2

          -  scheduled for aortic valve replacement surgery

        Exclusion Criteria:

          -  combined surgery (plus coronary artery bypass graft or other valve
             replacement/plasty)

          -  Infective Endocarditis

          -  previously known haemostatic disorder

          -  previous treatment with oral anticoagulants or IIb-IIIa inhibitors (we did not
             exclude those on acetyl-salicylic acid)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>esperanza carrasco, anesthesiologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>rodrigo lopez, anesthesiologist</last_name>
    <role>Study Director</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>guillermo lema, profesor titular</last_name>
    <role>Study Chair</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Universidad Católica de Chile</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 19, 2013</lastchanged_date>
  <firstreceived_date>November 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pontificia Universidad Catolica de Chile</investigator_affiliation>
    <investigator_full_name>MPoblete</investigator_full_name>
    <investigator_title>Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>acquired von Willebrand disease</keyword>
  <keyword>severe aortic stenosis</keyword>
  <keyword>Heye´s syndrome</keyword>
  <keyword>desmopressin</keyword>
  <keyword>von Willebrand multimers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
